Journal of Molecular and Cellular Cardiology
Volume 50, Issue 3 , Pages 426-432 , March 2011

Critical role for white blood cell NAD(P)H oxidase-mediated plasminogen activator inhibitor-1 oxidation and ventricular rupture following acute myocardial infarction

  • Udit Agarwal

      Affiliations

    • Department of Cardiovascular Medicine and Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, OH, USA
    • School of Biomedical Sciences, Kent State University, Kent, OH, USA
    • ,
  • Xiaorong Zhou

      Affiliations

    • Department of Cardiovascular Medicine and Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, OH, USA
    • ,
  • Kristal Weber

      Affiliations

    • Department of Cardiovascular Medicine and Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, OH, USA
    • ,
  • Alisher R. Dadabayev

      Affiliations

    • Department of Cardiovascular Medicine and Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, OH, USA
    • ,
  • Marc S. Penn

      Affiliations

    • Department of Cardiovascular Medicine and Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, OH, USA
    • Corresponding Author InformationCorresponding author. Skirball Laboratory for Cardiovascular Cellular Therapeutics, Departments of Cardiovascular Medicine and Stem Cell Biology, Cleveland Clinic, NE30, 9500 Euclid Ave, Cleveland, OH 44195, USA. Tel.: +1 216 445 1932.

Received 29 March 2010 ,Revised 9 August 2010 ,Accepted 23 August 2010.

References 

  1. Przyklenk K, Connelly CM, McLaughlin RJ, Kloner RA, Apstein CS. Effect of myocyte necrosis on strength, strain, and stiffness of isolated myocardial strips. Am Heart J. 1987;114:1349–1359
  2. Penn MS. The role of leukocyte-generated oxidants in left ventricular remodeling. Am J Cardiol. 2008;101:30D–33D
  3. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135–1142
  4. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res. 2004;95:637–644
  5. Askari A, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JT, et al. Myeloperoxidase and plasminogen activator inhibitor-1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615–624
  6. Strandberg L, Lawrence DA, Johansson LB, Ny T. The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the P1' methionine. J Biol Chem. 1991;266:13852–13858
  7. Sigurdardottir O, Wiman B. Identification of a PAI-1 binding site in vitronectin. Biochim Biophys Acta. 1994;1208:104–110
  8. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM, et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res. 2007;100:894–903
  9. Liu YH, Carretero OA, Cingolani OH, Liao TD, Sun Y, Xu J, et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol. 2005;289:H2616–H2623
  10. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation. 2004;110:412–418
  11. Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD–SCID mice reveals a new class of human stem cells. Nat Med. 2003;9:959–963
  12. Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW, et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation. 2005;112:2812–2820
  13. Arndt PG, Young SK, Poch KR, Nick JA, Falk S, Schrier RW, et al. Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways. J Immunol. 2006;177:7233–7241
  14. Thorsen S, Mullertz S, Suenson E, Kok P. Sequence of formation of molecular forms of plasminogen and plasmin–inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochem J. 1984;223:179–187
  15. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792–1801
  16. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest. 2008;118:3012–3024
  17. Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest. 2005;115:879–887
  18. Barnes JL, Mitchell RJ, Torres ES. Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. J Histochem Cytochem. 1995;43:895–905
  19. Park YJ, Liu G, Lorne EF, Zhao X, Wang J, Tsuruta Y, et al. PAI-1 inhibits neutrophil efferocytosis. Proc Natl Acad Sci USA. 2008;105:11784–11789
  20. Wojta J, Kaun C, Zorn G, Ghannadan M, Hauswirth AW, Sperr WR, et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood. 2002;100:517–523
  21. Yang F, Liu YH, Yang XP, Xu J, Kapke A, Carretero OA. Myocardial infarction and cardiac remodelling in mice. Exp Physiol. 2002;87:547–555
  22. Zaman AK, Fujii S, Schneider DJ, Taatjes DJ, Lijnen HR, Sobel BE. Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants. Histochem Cell Biol. 2007;128:135–145
  23. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension. 2008;51:319–325
  24. Teshima Y, Yufu K, Akioka H, Iwao T, Anan F, Nakagawa M, et al. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. J Cardiol. 2009;53:58–64
  25. Kanadasi M, Cayli M, Demirtas M, Inal T, Demir M, Koc M, et al. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart Vessels. 2006;21:291–297
  26. Gurgun C, Ildizli M, Yavuzgil O, Sin A, Apaydin A, Cinar C, et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol. 2008;123:102–107

☆ This work was funded by the Skirball Foundation.

PII: S0022-2828(10)00327-5

doi: 10.1016/j.yjmcc.2010.08.024

Journal of Molecular and Cellular Cardiology
Volume 50, Issue 3 , Pages 426-432 , March 2011

Article Tools

* Image Usage & Resolution